Scope Biosciences B.V.

Scope Biosciences develops ScopeDx: the next generation of molecular diagnostics. This platform technology uses proprietary Type III CRISPR-Cas to detect nucleic acid sequences. Transforming our ability to detect genetic material with ease, speed and incredible accuracy.

Niek Savelkoul

CEO Scope Biosciences

Jurre Steens

CSO Scope Biosciences

All organisations from A to Z